Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 3
2007 3
2008 2
2009 4
2010 4
2011 2
2012 8
2013 13
2014 11
2015 12
2016 11
2017 13
2018 20
2019 29
2020 47
2021 46
2022 26
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Results by year

Filters applied: . Clear all
Page 1
The role of preoperative immune cell metrics in renal cell carcinoma with a tumor thrombus.
Sandberg M, Namugosa M, Ritts R, Costa CM, Temple D, Hayes M, Whitman W, Ye E, Refugia J, Ben-David R, Alerasool P, Eilender B, Zanotti RR, Mourão TC, Kim JK, Marchiñena PG, Byun SS, Abreu D, Mehrazin R, Spiess P, de Cassio Zequi S, Rodriguez A. Sandberg M, et al. Among authors: costa cm. Urologia. 2024 Apr 25:3915603241248020. doi: 10.1177/03915603241248020. Online ahead of print. Urologia. 2024. PMID: 38661082
Tirbanibulin: an alternative topical approach to manage superficial basal cell carcinoma. Comment on: 'Successful treatment of field cancerization on the dorsum of the hands with 1% tirbanibulin ointment'.
Martora F, Ascierto P, Palla M, Costa C, D'Andrea M, Di Trolio R, Scarpato L, Marasca C. Martora F, et al. Among authors: costa c. Clin Exp Dermatol. 2023 Nov 16;48(12):1373-1374. doi: 10.1093/ced/llad271. Clin Exp Dermatol. 2023. PMID: 37566741 No abstract available.
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire.
Camela E, Villani A, Ocampo Garza SS, Costa C, Fabbrocini G, Megna M, Potestio L, Ruggiero A, Scalvenzi M. Camela E, et al. Among authors: costa c. Dermatol Pract Concept. 2023 Jul 1;13(3):e2023177. doi: 10.5826/dpc.1303a177. Dermatol Pract Concept. 2023. PMID: 37557166 Free PMC article.
249 results